Completed PHASE4 INTERVENTIONAL NCT00292487

Patients With Renal Impairment Undergoing CT

Isovue and Visipaque in Renally Impaired Patients Undergoing CT

Sponsor: Bracco Diagnostics, Inc

Updated 5 times since 2017 Last updated: Feb 7, 2012 Started: Nov 30, 2004 Primary completion: Feb 28, 2006 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00292487, this PHASE4 trial focuses on Contrast Induced Nephropathy and remains completed. Sponsored by Bracco Diagnostics, Inc, it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bracco Diagnostics, Inc

Data source: Bracco Diagnostics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Princeton, United States